AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05202496 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic treatment
Description: experimental group subjects undergo orthodontic treatment after extraction of premolars
Study NCT04216329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selective serotonin receptor (5-HT3) antagonists
Description: Anti-emetic for breakthrough nausea.
Study NCT04216329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 2.5mg to 5mg once a day if weight loss is rapid.
Study NCT04216329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salt tablets
Description: To treat hyponatremia, add salt tablets to participants diet per institutional guidelines.
Study NCT04216329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-diarrheal
Description: Treat diarrhea with an anti-diarrheal per institutional guidelines
Study NCT00806117 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy (RT)
Description: External irradiation 50Gy/5 weeks~* Lateral: 2 cm lateral to the bony margin of the pelvis~* Superior: Between L5 and S1~* Inferior: 2 cm below the obturator foramen Intracavitary boost 30-35Gy/4 weeks(positive vaginal margins only)
Study NCT00835666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg tablets
Description: 1 x 5 mg, single dose fasting
Study NCT00835666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROSCAR®
Description: 1 x 5 mg, single dose fasting
Study NCT00806117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent chemoirradiation (CCRT)
Description: Cisplatin 40mg/m2 every week during external irradiation
Study NCT00806117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequence chemotherapy and radiotherapy (SCRT)
Description: Paclitaxel 135\~175mg/m2 over 3 hours Cisplatin 60\~75mg/m2
Study NCT03656393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib (250 mg, orally, every day) for 56 days
Study NCT03656393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine (60 mg/m2, orally, Once every three weeks) for 6 weeks
Study NCT05751525 — intervention group
Intervention type: DRUG
Intervention: Sulfonylurea
Description: Glibenlclamide / glyburide
Study NCT03656393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin (AUC5, intravenously drip, once a week) for 6 weeks
Study NCT01281553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension identical in appearance to cisapride q.i.d. for 8 weeks.
Study NCT01281553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisapride
Description: 0.2 mg/kg suspension q.i.d.for 8 weeks.
Study NCT03893487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimepinostat
Description: Fimepinostat capsules
Study NCT03893487 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT04450069 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CLBR001 and SWI019
Description: Investigational immunotherapy for B cell malignancies
Study NCT00859521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: 1000 mg Tablet
Study NCT00859521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keppra®
Description: 1000 mg Tablet
Study NCT02855853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: serious game et virtual reality
Study NCT02855853 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nintendo Wii
Study NCT02724605 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Red blood cells unit age 14 days or less
Description: 30 Patients who will receive units of packed red blood cells stored stored for 14 days or less
Study NCT02724605 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Red blood cells unit age more than 14 days
Description: 30 patients who will receive units of packed red blood cells stored for more than 14 days
Study NCT01693523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg by mouth two times a day (200 mg/day).
Study NCT01693523 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules by mouth twice a day.
Study NCT01693523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
Study NCT01020331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Study NCT01693523 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
Study NCT04538677 — intervention group
Intervention type: DEVICE
Intervention: Video consultation
Description: A two-way audio and visual connection between patients and surgeons
Study NCT01368991 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kryptonite
Description: Osteoconductive biologic bone cement to be applied upon sternal closure
Study NCT01368991 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional closure
Description: conventional closure, no kryptonite applied
Study NCT00849823 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Male Sexual Health Program
Description: An attention equivalent control condition entailing a 60-minute one-to-one session that will didactically teach teens about several aspects of male sexual health. The content and objectives are related only to knowledge acquisition. In addition to this program, teens randomized to the control condition will receive standard-of-care services from the clinic. This involves the provision of free condoms (one size fits all condoms) and a brief (nurse-delivered) counseling message to practice safer sex.
Study NCT00849823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus on the Future Program
Description: A 60-minute, theory-guided program designed to increase the quality and frequency of teens' condom use within the context of making safer choices regarding partners and sexual behaviors. The program is explicitly designed to increase the quality and frequency of teen's condom use.
Study NCT03498235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: In Team Sevoflurane,patients undergo sevoflurane.
Study NCT03308643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Patients will receive intravenous oxytocin infusion just before the surgery after the induction of general anesthesia.
Study NCT03308643 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Patients will receive intravenous normal saline infusion just before the surgery after the induction of general anesthesia.
Study NCT02288871 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Cardiac CT-scan
Description: ECG gated CT angiography of the heart will be performed on a 128-slice dual-source and two Stellar detectors CT system with retrospective ECG-gating (Siemens/SOMATOM Definition Flash - Siemens, Germany, 100kV, 395.75 mAs).~In details, multi-phase images will be acquired to reconstruct between 10 and 100% of the cardiac cycle (10% increments) with a slice thickness of 1 mm. Examination will include left ventricular outflow tract, aortic root, coronary sinus, ascending aorta together with the prosthetic valves.
Study NCT03498235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: In Team Propofol ,anesthesia is maintained with propofol
Study NCT02916446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viaskin Peanut 250 mcg
Study NCT00472212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Hyperopic spectacle lenses
Study NCT01946802 — intervention group
Intervention type: DEVICE
Intervention: Frontal 4 channel EEG
Description: Simultaneous conventional EEG and SEDline monitoring for 30 minutes during and after therapeutic hypothermia
Study NCT00452257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 mg loading dose then 500 mg, oral, daily, up to 3 years or until progressive disease
Study NCT01332201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: oral
Study NCT01332201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: oral
Study NCT00472212 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Plano (no power, control) spectacle lenses
Study NCT01282320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention program
Description: Individually tailored exercise programme (combination of pilates and aerobe training) with one hour activity sessions two-three times per week in 16 weeks.
Study NCT02916446 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02472483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and Behavior Therapy (CBT)
Description: 20-weeks CBT
Study NCT02472483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy (MBCT)
Description: 8-weeks MBCT
Study NCT00118144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00863668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz + Tenofovir DF/Emtricitabine
Description: 600mg QD for 52 weeks + 300mg/200mg QD for 52 weeks
Study NCT00604786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: Dosing is based on IgE level and weight given every 2 or 4 weeks
Study NCT00604786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Dosing is based on IgE level and weight given every 2 or 4 weeks
Study NCT01518114 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: Exercise will be performed under continuous telemetry monitoring and medical supervision. Each session will include 5-10 worm-up, 30 min of aerobic activity on treadmill or bicycle ergometer followed by 10-15 min of stretch and relaxation exercise. Blood pressure will be obtained before the onset and at the end of each session. Participants will be requested to rest and observed 15-30 min before going home. The exercise intensity will be monitored and adjusted, per protocol, according to RPE using the Borg scale.
Study NCT01518114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Exercise will be performed under continuous telemetry monitoring and medical supervision. Each session will include 5-10 worm-up, 30 min of aerobic activity on treadmill or bicycle ergometer followed by 10-15 min of stretch and relaxation exercise. Blood pressure will be obtained before the onset and at the end of each session. Participants will be requested to rest and observed 15-30 min before going home. The exercise intensity will be monitored and adjusted, per protocol, according to RPE using the Borg scale.
Study NCT03993405 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonographic evaluation
Description: Ultrasonographic measurement is assessment method to diagnosis of sarcopenia
Study NCT03993405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasonographic evaluation
Description: Ultrasonographic measurement is assessment method to diagnosis of sarcopenia
Study NCT01398501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Oral, 200 to 400 mg QD or BID
Study NCT00863668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir + Tenofovir DF/Emtricitabine
Description: 400mg BID for 52 weeks + 300mg/200mg QD for 52 weeks
Study NCT00863668 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy with biopsies
Description: Day 0, Day 2, Day 7, Day 14, Week 52
Study NCT01438671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit
Description: The Nintendo Wii Fit is an accessory for the Nintendo Wii video game system that utilizes a balance board peripheral. The subject stands on the balance board and engages in video games that require weight shifting and balancing in order to interact with the game. This intervention will be administered for 30 minutes, 3 to 5 times per week (as tolerated by subject), for a two week period.
Study NCT01438671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional balance training
Description: This physical therapy intervention involves gait training, balance education on various surfaces, activities involving limited and changing bases of support, and dynamic interaction with the subject's environment. This intervention will be administered 30 minutes per day, 3 to 5 days per week (by subject's tolerance), for a two week period.
Study NCT00863668 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy with biopsies
Description: Day 0, Day 2, Day 7, Day 14, Week 52
Study NCT00863668 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal Lymph Node Excision
Description: Day 0, Day 2, Day 7, Day 14, Week 52
Study NCT00863668 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inguinal Lymph Node Excision
Description: Day 0, Day 2, Day 7, Day 14, Week 52
Study NCT01480180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa pegol
Description: Administered i.v.
Study NCT01039168 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Workplace dialogue
Study NCT01039168 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Care as usual
Study NCT00936949 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical approach
Description: Using a gluteus maximus split, the posterolateral approach remains posterior to the gluteus medius and minimus. Exposure of the hip and proximal femur requires division of the posterior hip capsule and the external rotators. The exposure and dislocation are completed with flexion and internal rotation of the femur. After arthroplasty, the external rotators and posterior capsule was routinely repaired using a heavy absorbable suture.
Study NCT00936949 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified lateral approach
Description: The operative technique described modified lateral approach as described by Mulliken et al.
Study NCT02585791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propylene Glycol
Description: inhaled Propylene Glycol (PG) by vaporing
Study NCT01631552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy (SG)
Description: Administered via intravenous (IV) infusion
Study NCT03480763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
Study NCT03480763 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose
Study NCT03480763 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PNEUMOVAX™23
Description: 23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
Study NCT03480763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNEUMOVAX™23
Description: 23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
Study NCT00725322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A
Description: Subcutaneous injection of Botulinum Toxin Type A into the patient's scar tissue
Study NCT00725322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Saline
Description: Subcutaneous Saline injection given at site of scar neuroma
Study NCT00990535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide-LAR
Description: Octreotide-LAR 30 mg administered every 21 days until progression
Study NCT03072030 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GamEvac-Combi (vaccine)
Description: vaccination
Study NCT03072030 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vaccination
Study NCT01776138 — intervention group
Intervention type: OTHER
Intervention: Collect Blood and Survey Instruments
Study NCT00025675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gefitinib
Study NCT03413267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Custard
Description: Food matrix: custard (liquid emulsion)
Study NCT01968876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Adherence Smartphone App
Description: MyMedSchedule is a consumer-grade smartphone application currently available on various marketplaces of the Android and iOS platforms that acts as a portal to the free service MyMedSchedule.com website. It can interface with the MedActionPlan discharge planning tool for providers by automatically populating fields, allowing medication lists to be pushed to a subject's MyMedSchedule account, allowing the input of complex medication regimens, and aiding in medication reconciliation. A MyMedSchedule account can be setup with the patient's name, date of birth, allergies, emergency contact, healthcare providers, insurance plan information, and complete medication list. Medication dose and refill reminders can be set and sent through short message service (SMS) text message or e-mail. SMS text message reminders will be used for this study.
Study NCT00603044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone furoate
Description: treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy
Study NCT03413267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flan
Description: Food matrix: flan (soft gel)
Study NCT03413267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sponge cake
Description: Food matrix: sponge cake (porous and spongy)
Study NCT03413267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biscuit
Description: Food matrix: biscuit (thick and crunchy)
Study NCT00655941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary instruction
Description: Weekly instruction by dieticians
Study NCT00655941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Supervised exercise in groups
Study NCT04488211 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: The IVM survey will be structured as a series of open questions and multiple-choice questions.
Study NCT01419262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D - Cholecalciferol 400 IU
Description: One drop per day (liquid), 400 IU, 4 to 9 months depending on date of enrollment and date of follow-up
Study NCT01419262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 - Cholecalciferol 2000 IU
Description: One drop per day (liquid), 2000 IU, 4 to 9 months depending on date of enrollment and date of follow-up
Study NCT02277613 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMI MultiStem cells
Description: AMI MultiStem cells administration in coronary artery with a micro-infusion catheter.
Study NCT02277613 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham procedure using Micro-Infusion Catheter in coronary artery without injection.
Study NCT02179632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to disclosure website
Description: Participants are exposed to a physician payment disclosure website.
Study NCT02682329 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogen Peroxide and Carbamide Peroxide
Description: Carbamide Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP 10% at home and HP 40% at office
Study NCT02458456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric resistance training
Description: Isometric exercise using a hand dynamometer.
Study NCT02458456 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Isometric resistance training
Description: Isometric exercise using a hand dynamometer.
Study NCT04068584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart Angel
Description: Patient issued with a tablet with the Smart Angel application to monitor clinical signs and symptoms
Study NCT03816501 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: music
Description: The preference of the patients will be listened to preoperatively through the headphones
Study NCT03816501 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no music
Description: the patients will not be listened